The world of cancer research is filled with intriguing paradoxes, and the story of the MLL4 protein is a prime example. This seemingly ordinary epigenetic modifier has revealed an unexpected dual role in cancer regulation, leaving scientists with a captivating enigma.
Unveiling the Enigma of MLL4
In the realm of cancer research, the MLL4 protein has emerged as a fascinating subject of study. Initially, its name might not suggest its importance, but its functions are anything but ordinary. MLL4, a member of the mixed-lineage leukemia family, has shown a paradoxical behavior in different types of cancer. In leukemia, it acts as a driver of disease progression, while in solid tumors, it takes on the role of a suppressor. This dichotomy caught the attention of Robert Roeder, a pioneer in genetic transcription at Rockefeller University.
Roeder's team, based in the Laboratory of Biochemistry and Molecular Biology, embarked on a journey to unravel the mysteries of MLL4. Their research, published in Molecular Cell, has shed light on previously unknown characteristics of this protein, particularly its relationship with the tumor-suppressing protein p53.
The Guardian's Unlikely Ally
MLL4 belongs to a family of histone lysine methyltransferases, each with a unique role in regulating gene activation. What sets MLL4 apart is its ability to methylate histone 3 at lysine 4, a process that controls downstream gene activation. Its presence in virtually all mammalian cells and its large size in the nucleus highlight its significance.
In MLL-rearranged leukemias, MLL4 protects leukemia cells from stress and maintains their undifferentiated state. However, in solid tumors, it teams up with p53, often referred to as "the guardian of the genome" due to its role in activating DNA damage response genes. The mutation of p53 itself is linked to various cancers, making this partnership even more intriguing.
Unraveling the Molecular Mystery
Jianfeng Sun, a structural biologist in Roeder's lab, recognized that a deeper understanding of MLL4's structure could provide insights into its cooperative role with p53. Sun employed a combination of cryo-EM imaging, genetics, and an in vitro transcription system to visualize the MLL4 complex. The imaging revealed a unique structural architecture, with MLL4 anchoring itself to the nucleosome while deploying a flexible "arm" to tag histones with methylation markers, essentially acting as a gene activation switch.
Furthermore, Sun's team found that the N-terminal region of MLL4 folds back onto the C-terminal region, a feature essential for its transcriptional coactivation function and its collaboration with p53. When MLL4 was genetically knocked out, the genes targeted by p53 were less likely to be activated, indicating that MLL4 is crucial for p53's effectiveness as a transcription factor.
A Tale of Two Functions
Roeder emphasizes the surprising nature of these findings. While MLL4's primary function is histone 3 methylation, it also acts as a direct p53 co-activator, a role previously unknown. This discovery opens up new avenues for research, as scientists aim to understand how MLL4 interacts with leukemia transcription factors and how it can support both leukemia-associated programs and tumor suppression.
In conclusion, the story of MLL4 is a testament to the complexity of cancer biology. Its dual role in cancer regulation highlights the intricate molecular mechanisms at play. As researchers continue to explore these mechanisms, they inch closer to unraveling the mysteries of cancer and developing more effective treatments.
